Effect of adjusting the trigger drug in antagonist scheme and luteal support program on pregnancy outcome

Objective To analyze the effect of adjusting the trigger drug in antagonist scheme and luteal support program on pregnancy outcome. Methods A total of 219 promoting gestation patients accepting IVF/ICSI-EF were divided into two groups: group A(frozen embyo first transplantation, n=53) and group B(fresh embyo transfer group, n=166). The subgroups were according to the ages: ≤35 years group, 36-40 years group, >40 years group. The general characteristics and clinical outcomes were compared among the groups. Results The general characteristics were comparable among the groups (P>0.05), except for the number of available embyos was higher in the >40 years group of group B(2.89±1.62 vs. 2.26±0.87, P 0.05). Conclusions For the non OHSS high-risk patients, To chooing HCG to induce oocyte maturationand enhance the luteal phase support in the fresh embyo transfer cycle can gain satisfactory pregnancy outcomes. Especially for >40 years women, it is better to transfer in fresh cycle, with high efficacy and shorter clinical treatment duration. Key words: Gonadotropin-releasing hormone antagonist; Fresh embyo transfer cycle; Human chorionic gonadotropin triggering; In vitro fertilization-embryo transfer